The FDA has approved Taclonex, a combination topical consisting of calcipotriene 0.005% and betamethasone dipropionate 0.064%, for the treatment of psoriasis vulgaris in adults. Warner Chilcott plans to launch the new ointment in the first half of 2006.
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.